Effective Medications to Prevent Chronic Migraine Attacks
Chronic Migraine Prophylaxis is a cornerstone in managing patients who suffer from 15 or more headache days every month. Recent clinical evidence highlights several effective pharmacological options that significantly reduce the burden of this condition. Selecting the right preventive treatment can transform a patient’s quality of life by decreasing attack frequency. Consequently, doctors must stay updated on the latest therapeutic advancements.
Evolving Options for Chronic Migraine Prophylaxis
High-certainty evidence strongly supports the use of calcitonin gene-related peptide (CGRP) targeted therapies. Specifically, medications like eptinezumab, erenumab, fremanezumab, and galcanezumab show substantial efficacy. These treatments typically reduce monthly migraine days by approximately two compared to a placebo. Additionally, atogepant offers a robust oral alternative for long-term prevention. However, clinicians should note that while botulinum toxin may help, its evidence certainty remains low. Furthermore, rimegepant probably has no significant effect on chronic migraine frequency based on current data.
Tolerability and Safety Considerations
Patient adherence depends heavily on the side-effect profile of the chosen medication. For instance, galcanezumab effectively reduces the likelihood of treatment dropout compared to placebo. Conversely, botulinum toxin often leads to higher discontinuation rates due to adverse events. While older drugs like topiramate and valproate were once common, recent studies on them are sparse and carry a high risk of bias. Therefore, modern biologics generally provide a more predictable safety profile for most patients. Choosing these newer agents can lead to better long-term outcomes and higher patient satisfaction.
Frequently Asked Questions
Q1: Which drugs are most effective for chronic migraine prophylaxis?
Eptinezumab, erenumab, fremanezumab, galcanezumab, and atogepant show the strongest evidence for efficacy in reducing monthly migraine days.
Q2: How does botulinum toxin compare to CGRP therapies?
Botulinum toxin may slightly reduce migraine days, but it has lower certainty of evidence and higher adverse event-related discontinuation rates compared to CGRP therapies.
Q3: Is rimegepant recommended for preventing chronic migraines?
Current moderate-certainty evidence suggests that rimegepant probably has no significant effect on reducing frequency in chronic migraine prophylaxis.
References
- Khalili M et al. Effectiveness and Tolerability of Pharmacologic Prophylaxis for Chronic Migraine : A Systematic Review of Randomized Controlled Trials. Ann Intern Med. 2026 May 05. doi: 10.7326/ANNALS-25-02221. PMID: 42081823.
- Pfizer India. Pfizer Launches CGRP Receptor Antagonist Rimegepant for Migraine Treatment in India. Express Pharma. Nov 2025.
- Indian Medical Association. Headache management algorithm for general practitioners in India. IMA-India. 2024.